SEREVENT DISKUS (salmeterol xinafoate inhalation powder) contains salmeterol xinafoate as the racemic form of the 1-hydroxy-2-naphthoic acid salt of salmeterol. The active component of the formulation is salmeterol base, a highly selective beta2-adrenergic bronchodilator.
SEREVENT DISKUS is indicated for the following:
Asthma: SEREVENT DISKUS is indicated for long-term, twice-daily (morning and evening) administration in the maintenance treatment of asthma and in the prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma, who require regular treatment with inhaled, short-acting beta2-agonists. It is not indicated for patients whose asthma can be managed by occasional use of inhaled, short-acting beta2-agonists.
SEREVENT DISKUS is also indicated for prevention of exercise-induced bronchospasm in patients 4 years of age and older.
SEREVENT DISKUS may be used alone or in combination with inhaled or systemic corticosteroid therapy.
Chronic Obstructive Pulmonary Disease: SEREVENT DISKUS is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
Published Studies Related to Serevent Diskus (Salmeterol Inhalation Powder)
Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. [2011.03]
This 52-week study was designed to assess the safety and efficacy of fluticasone propionate/salmeterol combination (FSC) 250/50 micrograms versus fluticasone propionate (FP) 250 micrograms in subjects with persistent asthma symptomatic on open-label FP 100 micrograms.In addition, FSC 250/50 micrograms-treated subjects experienced fewer severe asthma exacerbations than subjects treated with FP 250 micrograms.
Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. [2010.11.15]
RATIONALE: For children with symptomatic asthma despite low to moderate doses of inhaled corticosteroids, evidence is still lacking whether to add a long-acting bronchodilator or to increase the dose of inhaled corticosteroids. OBJECTIVE: To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 mug twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 mug twice a day Diskus in children with symptomatic asthma... CONCLUSIONS: In our study the efficacy on symptom control and lung function of the combination of a long-acting bronchodilator with inhaled corticosteroid is equal to doubling the dose of the inhaled corticosteroid in children still symptomatic on a moderate dose of inhaled corticosteroid.
Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma. [2010.09]
Based primarily on extrapolation from adult studies, current pediatric asthma guidelines advise the addition of long-acting beta-agonists for children symptomatic on low/moderate-dose inhaled corticosteroids before increasing the corticosteroid dose... Addition of salmeterol provides greater improvement in sR(aw) than doubling the dose of FP in children with moderate/severe persistent asthma.
Childhood evaluation of salmeterol tolerance--a double-blind randomized controlled trial. [2010.03]
Long acting beta(2)-agonists (LABA) are widely used in children with asthma...
Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study. 
BACKGROUND AND OBJECTIVE: Inhaled corticosteroid (ICS)/long-acting beta(2)-agonist (LABA) combinations are the preferred maintenance therapy for adult asthma patients uncontrolled by ICS alone. Supporting data are largely from mixed populations of adolescents and adults, although ICS/LABA combinations are not approved for adolescents in all countries. This analysis evaluates overall asthma control in asthma patients aged >or=16 years receiving ICS/LABA combinations... CONCLUSIONS: This post hoc analysis supports the use of ICS/LABA combinations in adults aged >or=16 years.
Clinical Trials Related to Serevent Diskus (Salmeterol Inhalation Powder)
Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography [Recruiting]
This is a PI-initiated study taking place only at UCLA, sponsored by Sunovion. The
investigators plan to enroll about 20 subjects who are at least 40 years old and have
Chronic Obstructive Pulmonary Disease (COPD). The purpose of this study is to compare the
effectiveness of Brovana and Serevent in helping relieve COPD symptoms. Specifically, the
investigators are looking at how much and for how long the two drugs can open up the small
airways in the lungs. This will be done with breathing tests on all subjects, and with high
resolution CT scans on subjects who agree to this optional part of the study. Half of
subjects will take Brovana (arformoterol tartrate inhalation solution) for 2 weeks and then
Serevent (salmeterol xinafoate inhalation powder) for 2 weeks; the other half will take
Serevent the first two weeks and Brovana the second two weeks. All subjects will also take
Spiriva (tiotropium) and will be provided with albuterol for immediate relief of symptoms.
After a Screening Visit to determine eligibility, subjects will be randomly assigned to
receive Brovana or Serevent for the first 2 weeks, complete Test Visit 1, then receive the
other study drug for 2 weeks, and finally complete Test Visit 2. Visits will include
questionnaires, review of health and medications, and breathing tests before and after
taking the study drug. Subjects who agree to be in the sub-study will also undergo CT scans
before and after taking the study drug at both test visits.
Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients [Completed]
The cardiovascular component associated with COPD plays a major role in prognosis of the
disease, being responsible of 25% of the deaths. Experimental and initial clinical data
suggest that beta-adrenergic agonists accelerate clearance of excess fluid from the alveolar
airspace, with potential positive effect on cardiogenic pulmonary edema.
The aim of this study was to investigate the effects of a long-acting beta-2 agonist,
salmeterol, on alveolar fluid clearance in COPD patients by evaluating the diffusive and
mechanical lung properties. Our experimental model to test alveolar fluid clearance was
rapid saline intravenous infusion.
Ten COPD and 10 healthy subjects treated with salmeterol or placebo 4 hours before the begin
of the study were evaluated, in four non consecutive days, just before and after a saline
infusion or a similar period without infusion.
Both in COPD and healthy subjects rapid saline infusion, with placebo or salmeterol
premedication, lead to a significant decrease of DLCO and FEV1. Nonetheless, salmeterol
pretreatment lead to a significant reduction of the impairment of gas exchange due to saline
infusion (-64% of DLCO reduction in comparison with placebo), whilst it did not affect the
changes in FEV1. In the control setting, with no infusion, we did not find any significant
change of both DLCO and mechanical properties of the lung.
In conclusions, in COPD patients salmeterol appears to provide a protective effect against
an acute alveolar fluid clereance challenge secondary to lung fluid overload providing an
intriguing mechanistic explanation for the benefits observed in larger trials.
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate [Completed]
This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood
sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done
during the study. Study medicines and procedures will be provided at no cost. Patients will
be treated with VENTOLIN (8 wks), ATROVENT (8 wks), then ADVAIR or SEREVENT (16 wks).
ADVAIR and SEREVENT are FDA approved for the treatment of asthma in patients 4 years of age
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 [Completed]
To demonstrate the non-inferiority of QVA149 110/50 Âµg o. d. to fluticasone/salmeterol 500/50
Âµg b. i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours
15 min and 23 hours 45 min post QVA149 dose) following 26 weeks of treatment in patients
with moderate to severe COPD
A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler [Withdrawn]
The Fluticasone Propionate/Salmeterol combination (FSC) at a dose of 100/50 micrograms (mcg)
twice daily in DISKUS inhaler (also known as ACCUHALER®, Ddpi) inhaler is a recognised and
licensed therapy for the treatment of asthma. GlaxoSmithKline (GSK) is developing the
ROTAHALER/ ROTACAPSÂ® (Rdpi) inhaler as an alternative treatment option for asthmatic
patients. This study is a Phase I, randomised, double-blind, double-dummy, two- treatment,
four-way cross-over (replicate design), two sequence, repeat dose, two centre study in mild
to moderate asthmatics to compare the pharmacokinetics and pharmacodynamics of fluticasone
proprionate/salmeterol (100/50 mcg) delivered via the Rdpi versus the Ddpi. A total of 58
subjects will be enrolled to ensure 52 subjects complete all dosing occasions. Each subject
will be allocated to one of two treatment sequences and will participate in four treatment
periods, receiving each of the treatments twice.
DISKUS, ACCUHALER, ROTAHALER and ROTACAPS are registered trademarks of GSK groups of
Page last updated: 2011-12-09